These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 23441216)

  • 1. Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor.
    Asai H; Fujiwara H; An J; Ochi T; Miyazaki Y; Nagai K; Okamoto S; Mineno J; Kuzushima K; Shiku H; Inoue H; Yasukawa M
    PLoS One; 2013; 8(2):e56820. PubMed ID: 23441216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b.
    Craddock JA; Lu A; Bear A; Pule M; Brenner MK; Rooney CM; Foster AE
    J Immunother; 2010 Oct; 33(8):780-8. PubMed ID: 20842059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptor.
    Tamanaka T; Oka Y; Fujiki F; Tsuboi A; Katsuhara A; Nakajima H; Hosen N; Nishida S; Lin YH; Tachino S; Akatsuka Y; Kuzushima K; Oji Y; Kumanogoh A; Sugiyama H
    Anticancer Res; 2012 Dec; 32(12):5201-9. PubMed ID: 23225417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor.
    Moon EK; Carpenito C; Sun J; Wang LC; Kapoor V; Predina J; Powell DJ; Riley JL; June CH; Albelda SM
    Clin Cancer Res; 2011 Jul; 17(14):4719-30. PubMed ID: 21610146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.
    Ochi T; Fujiwara H; Okamoto S; An J; Nagai K; Shirakata T; Mineno J; Kuzushima K; Shiku H; Yasukawa M
    Blood; 2011 Aug; 118(6):1495-503. PubMed ID: 21673345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
    Li X; Yao W; Yuan Y; Chen P; Li B; Li J; Chu R; Song H; Xie D; Jiang X; Wang H
    Gut; 2017 Jan; 66(1):157-167. PubMed ID: 26452628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model.
    Wang Y; Wang J; Yang X; Yang J; Lu P; Zhao L; Li B; Pan H; Jiang Z; Shen X; Liang Z; Liang Y; Zhu H
    Front Immunol; 2021; 12():628906. PubMed ID: 33777013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells.
    Kondo K; Fujiki F; Nakajima H; Yatsukawa E; Morimoto S; Tatsumi N; Nishida S; Nakata J; Oka Y; Tsuboi A; Hosen N; Oji Y; Sugiyama H
    J Immunother; 2016 Apr; 39(3):127-39. PubMed ID: 26938946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells.
    Lin Y; Fujiki F; Katsuhara A; Oka Y; Tsuboi A; Aoyama N; Tanii S; Nakajima H; Tatsumi N; Morimoto S; Tamanaka T; Tachino S; Hosen N; Nishida S; Oji Y; Kumanogoh A; Sugiyama H
    J Immunother; 2013 Apr; 36(3):159-70. PubMed ID: 23502763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cytotoxicity of T cells transduced with WT1 peptide-specific T-cell receptor gene against human lung cancer cells in vitro].
    An J; Cai SW; Li Y; Zhang J
    Nan Fang Yi Ke Da Xue Xue Bao; 2014 Aug; 34(9):1319-23. PubMed ID: 25263367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells.
    Thomas S; Xue SA; Cesco-Gaspere M; San José E; Hart DP; Wong V; Debets R; Alarcon B; Morris E; Stauss HJ
    J Immunol; 2007 Nov; 179(9):5803-10. PubMed ID: 17947653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein.
    Veomett N; Dao T; Liu H; Xiang J; Pankov D; Dubrovsky L; Whitten JA; Park SM; Korontsvit T; Zakhaleva V; Casey E; Curcio M; Kharas MG; O'Reilly RJ; Liu C; Scheinberg DA
    Clin Cancer Res; 2014 Aug; 20(15):4036-46. PubMed ID: 24850840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes.
    Tsuji T; Yasukawa M; Matsuzaki J; Ohkuri T; Chamoto K; Wakita D; Azuma T; Niiya H; Miyoshi H; Kuzushima K; Oka Y; Sugiyama H; Ikeda H; Nishimura T
    Blood; 2005 Jul; 106(2):470-6. PubMed ID: 15790789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antileukemia multifunctionality of CD4(+) T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer.
    Fujiwara H; Ochi T; Ochi F; Miyazaki Y; Asai H; Narita M; Okamoto S; Mineno J; Kuzushima K; Shiku H; Yasukawa M
    Leukemia; 2015 Dec; 29(12):2393-401. PubMed ID: 26104661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1.
    Asemissen AM; Keilholz U; Tenzer S; Müller M; Walter S; Stevanovic S; Schild H; Letsch A; Thiel E; Rammensee HG; Scheibenbogen C
    Clin Cancer Res; 2006 Dec; 12(24):7476-82. PubMed ID: 17189421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma.
    van Amerongen RA; Hagedoorn RS; Remst DFG; Assendelft DC; van der Steen DM; Wouters AK; van de Meent M; Kester MGD; de Ru AH; Griffioen M; van Veelen PA; Falkenburg JHF; Heemskerk MHM
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35728869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells.
    Jaigirdar A; Rosenberg SA; Parkhurst M
    J Immunother; 2016 Apr; 39(3):105-16. PubMed ID: 26938944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transduction of a novel HLA-DRB1*04:05-restricted, WT1-specific TCR gene into human CD4+ T cells confers killing activity against human leukemia cells.
    Katsuhara A; Fujiki F; Aoyama N; Tanii S; Morimoto S; Oka Y; Tsuboi A; Nakajima H; Kondo K; Tatsumi N; Nakata J; Nakae Y; Takashima S; Nishida S; Hosen N; Sogo S; Oji Y; Sugiyama H
    Anticancer Res; 2015 Mar; 35(3):1251-61. PubMed ID: 25750272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.